Entheon Biomedical Past Earnings Performance
Past criteria checks 0/6
Entheon Biomedical has been growing earnings at an average annual rate of 41.3%, while the Biotechs industry saw earnings growing at 13.8% annually. Revenues have been growing at an average rate of 90.9% per year.
Key information
41.3%
Earnings growth rate
63.3%
EPS growth rate
| Biotechs Industry Growth | 51.1% |
| Revenue growth rate | 90.9% |
| Return on equity | -115.9% |
| Net Margin | -214.3% |
| Last Earnings Update | 29 Feb 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Entheon Biomedical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 29 Feb 24 | 0 | 0 | 0 | 0 |
| 30 Nov 23 | 0 | 0 | 1 | 0 |
| 31 Aug 23 | 0 | 0 | 1 | 0 |
| 31 May 23 | 0 | 0 | 1 | 0 |
| 28 Feb 23 | 0 | -1 | 2 | 1 |
| 30 Nov 22 | 0 | -2 | 3 | 1 |
| 31 Aug 22 | 0 | -3 | 4 | 1 |
| 31 May 22 | 0 | -5 | 4 | 1 |
| 28 Feb 22 | 0 | -7 | 5 | 1 |
| 30 Nov 21 | 0 | -8 | 7 | 1 |
| 31 Aug 21 | 0 | -10 | 6 | 1 |
| 31 May 21 | 0 | -9 | 5 | 1 |
| 28 Feb 21 | 0 | -7 | 3 | 1 |
| 30 Nov 20 | 0 | -4 | 1 | 0 |
Quality Earnings: ENBI is currently unprofitable.
Growing Profit Margin: ENBI is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ENBI is unprofitable, but has reduced losses over the past 5 years at a rate of 41.3% per year.
Accelerating Growth: Unable to compare ENBI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ENBI is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: ENBI has a negative Return on Equity (-115.93%), as it is currently unprofitable.